Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B

Study

Year

Country

Group

n

M/F

Age(yr)(mean ±SD)

Sun LJ et al. [14]

2009

China

Test

130

104/26

N/A

Cont.

130

104/26

N/A

Cui YL et al. [15]

2010

China

Test

34

3/31

39.35 ± 10.61

Cont.

37

6/31

41.03 ± 11.48

Mi Lj et al. [16]

2009

China

Test

30

30/712

38.4 ± 2.5

Cont.

28

24/3

38.3 ± 2.4

Zhang P [17]

2008

China

Test

48

38/10

47 ± 15.8

Cont.

44

36/8

48 ± 16.2

Han YH et al. [18]

2007

China

Test

58

36/22

N/A

Cont.

48

29/19

N/A

Yang DH et al. [19]

2004

China

Test

30

N/A

N/A

Cont.

41

N/A

N/A

He Y et al. [20]

2005

China

Test

13

11/2

38.2

Cont.

24

21/3

37.8

Liao JH et al. [21]

2004

China

Test

36

29/7

39.5 ± 17.6

Cont.

40

32/8

38.6 ± 16.8

Yuan J et al. [22]

2001

China

Test

20

17/3

35.1 ± 11.6

Cont.

20

20/0

34.8 ± 8.5

Zhang LQ et al. [23]

2006

China

Test

29

24/5

N/A

Cont.

20

18/2

N/A

Zhan GQ et al. [24]

2006

China

Test

62

N/A

N/A

Cont.

36

N/A

N/A

Cao L et al.[25]

2007

China

Test

45

N/A

N/A

Cont.

46

N/A

N/A

Zhu GL et al. [26]

2002

China

Test

31

25/6

N/A

Cont.

31

23/8

N/A

Zhou BX et al. [27]

2011

China

Test

21

16/5

37.2

Cont.

21

15/6

38.1

Guo JC et al. [28]

2002

China

Test

24

24/0

38 ± 17.1

Cont.

24

24/0

39 ± 18.4

Zhong YB et al. [29]

2007

China

Test

24

20/4

29.2 ± 16.8

Cont.

35

29/6

33.8 ± 18.7

Zhou XX et al. [30]

2007

China

Test

17

14/3

N/A

Cont.

18

15/3

N/A

Ding FY et al. [31]

2003

China

Test

38

31/7

N/A

Cont.

38

33/5

N/A

Pan JZ et al. [32]

2007

China

Test

40

N/A

N/A

Cont.

42

N/A

N/A

Wang Y et al. [33]

2003

China

Test

30

N/A

N/A

Cont.

30

N/A

N/A

Qin SJ et al. [34]

2003

China

Test

20

N/A

N/A

 

Cont.

15

N/A

N/A